Clinical drug development represents one of the most complex, resource-intensive, and highly regulated processes in modern medicine, requiring coordination across multiple stakeholders including pharmaceutical companies, regulatory agencies, healthcare providers, and patients. The pathway from initial clinical investigation to market approval involves navigating intricate regulatory frameworks, designing scientifically robust trials, ensuring patient safety while demonstrating therapeutic efficacy, and addressing substantial operational and financial challenges. This article examines the fundamental phases of clinical drug development, explores the regulatory landscapes established by major authorities such as the Food and Drug Administration, European Medicines Agency, and other international bodies, and analyzes critical challenges in trial design, execution, and data interpretation. Key themes include the evolution of adaptive trial methodologies, patient-centric approaches that incorporate real-world evidence and patient-reported outcomes, risk-benefit assessment frameworks, and the growing emphasis on precision medicine and biomarker-driven development. Regulatory science plays a pivotal role in shaping development timelines, with innovative pathways such as accelerated approval, breakthrough designation, and conditional authorization offering expedited routes for promising therapies. The article also addresses ongoing efforts toward global regulatory harmonization through initiatives like the International Council for Harmonisation, which aims to reduce redundancy and facilitate multinational drug development. Future perspectives highlight the integration of artificial intelligence, decentralized trials, and advanced analytics in transforming the clinical development paradigm while maintaining rigorous standards for safety and efficacy.